Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
X. Huang
No relevant relationships to disclose
Y. M. Ning
No relevant relationships to disclose
M. Mulquin
No relevant relationships to disclose
R. A. Madan
No relevant relationships to disclose
J. L. Gulley
No relevant relationships to disclose
P. G. Kluetz
No relevant relationships to disclose
D. Adelberg
No relevant relationships to disclose
P. M. Arlen
No relevant relationships to disclose
H. L. Parnes
No relevant relationships to disclose
B. Adesunloye
No relevant relationships to disclose
S. M. Steinberg
No relevant relationships to disclose
J. J. Wright
No relevant relationships to disclose
J. B. Trepel
No relevant relationships to disclose
C. Chen
No relevant relationships to disclose
C. Bassim
No relevant relationships to disclose
A. B. Apolo
No relevant relationships to disclose
W. D. Figg
No relevant relationships to disclose
W. L. Dahut
No relevant relationships to disclose